BC Innovations | May 24, 2018
Product R&D

Bias-less bispecifics

Taking a leaf from the small molecule playbook, cancer play Merus N.V. is bringing unbiased screening to the bispecifics space. The biotech is betting the approach can discover bispecific antibodies with novel activity against known...
BC Week In Review | Nov 4, 2016
Clinical News

Patritumab: Ph II ongoing

Daiichi said patritumab will be evaluated in the ongoing Phase II I-SPY 2 trial, which is designed to rapidly and inexpensively test compounds in biomarker-defined subgroups of patients with neoadjuvant breast cancer. The program uses...
BC Week In Review | Jun 6, 2016
Clinical News

Patritumab: Phase III discontinued

Daiichi discontinued the double-blind, placebo-controlled, international Phase III HER3-Lung trial of IV patritumab after an IDMC concluded the study’s first part assessing PFS did not meet the predefined efficacy criteria. The IDMC did not identify...
BioCentury | Mar 28, 2016

Canbridge can-can

Canbridge Life Sciences Ltd .'s deal with Aveo Pharmaceuticals Inc. will see the Chinese biotech developing its first programs outside Asia. But Chairman and CEO James Xue says the company is not deviating from its...
BioCentury | Sep 9, 2013

Setting Amgen's targets

Amgen Inc. 's proposed acquisition of Onyx Pharmaceuticals Inc. will more than double the bellwether's portfolio of marketed targeted cancer therapeutics, putting it in a tie with GlaxoSmithKline plc for second place behind Roche and...
BC Innovations | Jun 6, 2013
Cover Story

Driving cancer through ErbB3

Roche 's Genentech Inc. unit has shown that mutations in ERBB3 can drive oncogenesis by enhancing the receptor's ability to form a heterodimer with HER2 . 1 Because the process appears to depend on HER2, the...
BioCentury | Mar 7, 2011

Daiichi's U.S. comPlexx

Although Roche has worldwide rights to Plexxikon Inc. 's PLX4032 , the opportunity to jump start a U.S. commercial presence in cancer on the back of co-promotion rights is leading Daiichi Sankyo Co. Ltd. to acquire...
BC Innovations | Apr 1, 2010
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Ovarian cancer Epidermal growth factor receptor 3 (HER3; ERBB3) A cell culture and mouse study suggests that inhibiting ERBB3 could help treat a subset of...
BioCentury | Oct 5, 2009

Ebb & Flow

Of the $6.9 billion in biotech debt raised thus far in 2009, $1.9 billion (28%) was raised in the last two weeks through four financings: three bumped up deals by Elan Corp. plc (NYSE:ELN), Incyte...
BioCentury | Mar 30, 2009
Product Development

Uncooperative is good

Aveo Pharmaceuticals Inc. believes its antibodies targeting the ErbB3 receptor could reduce the incidence of treatment resistance seen with other EGFR inhibitors for cancer. Last week's deal with Biogen Idec Inc. will give Aveo the...
Items per page:
1 - 10 of 17